Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D3-Penta 21 DTG/3TC maintenance trial in virologically suppressed children with HIV
PACTR202112758618724Phase 3Not yet recruiting
- Sponsor
- Penta Foundation
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in human immunodeficiency virus infection (HIV) comparing DTG + 3TC fixed-dose maintenance with Standard of care (2 arms). Primary endpoint: Confirmed viral rebound by week 96. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
dolutegravirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202112758618724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202112758618724.